Literature DB >> 17309906

Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation.

Duk-Woo Park1, Cheol Whan Lee, Sung-Cheol Yun, Young-Hak Kim, Myeong-Ki Hong, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park.   

Abstract

OBJECTIVE: To determine the association of preprocedural C reactive protein (CRP) levels with angiographic restenosis and adverse clinical events after drug-eluting stent (DES) implantation.
DESIGN: A prospective cohort analysis of preprocedural CRP levels as a predictor of serious ischaemic complications or binary restenosis in patients treated with DES.
SETTING: Tertiary referral centre. PATIENTS: 1650 consecutive patients who underwent successful DES implantation. Patients were grouped into tertiles according to preprocedural CRP values for data analysis.
INTERVENTIONS: Successful DES implantation. MAIN OUTCOME MEASURES: The primary end point was a major coronary event, defined as cardiac death or Q-wave myocardial infarction.
RESULTS: Baseline clinical and angiographic characteristics were similar between the tertile groups, except that more patients had multivessel disease and acute coronary syndrome with increasing tertiles of CRP levels. At 1-year follow-up, a primary end point occurred in 4 (0.7%) patients of the lowest tertile, in 3 (0.5%) patients of the middle tertile and in 16 (2.9%) patients of the highest tertile (p = 0.003). In multivariate analysis, the highest tertile of CRP levels was an independent predictor of a major coronary event (HR 4.68, 95% CI 1.91 to 11.44, tertile III vs tertiles I and II, p = 0.001). However, restenosis rates were similar in all three groups (9.1% vs 11.4% vs 11.6%, respectively, p = 0.3).
CONCLUSIONS: Preprocedural CRP levels are significantly associated with major coronary events after DES implantation. However, preprocedural CRP levels do not predict subsequent restenosis. Baseline CRP levels may be useful to guide adjunctive management for preventing serious ischaemic events in patients undergoing DES implantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309906      PMCID: PMC1955033          DOI: 10.1136/hrt.2006.099762

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents.

Authors:  Achille Gaspardone; Francesco Versaci; Fabrizio Tomai; Carlo Citone; Igino Proietti; Gaetano Gioffrè; Olga Skossyreva
Journal:  Am J Cardiol       Date:  2006-03-20       Impact factor: 2.778

Review 2.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

3.  Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting.

Authors:  Alban Dibra; Julinda Mehilli; Siegmund Braun; Martin Hadamitzky; Hannsjörg Baum; Josef Dirschinger; Helmut Schühlen; Albert Schömig; Adnan Kastrati
Journal:  Am J Med       Date:  2003-06-15       Impact factor: 4.965

4.  Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation.

Authors:  D H Walter; S Fichtlscherer; M Sellwig; W Auch-Schwelk; V Schächinger; A M Zeiher
Journal:  J Am Coll Cardiol       Date:  2001-03-01       Impact factor: 24.094

5.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Authors:  Paul M Ridker; Nader Rifai; Lynda Rose; Julie E Buring; Nancy R Cook
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

6.  Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty.

Authors:  A Buffon; G Liuzzo; L M Biasucci; P Pasqualetti; V Ramazzotti; A G Rebuzzi; F Crea; A Maseri
Journal:  J Am Coll Cardiol       Date:  1999-11-01       Impact factor: 24.094

7.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

8.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

9.  The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study.

Authors:  Michael N Zairis; John A Ambrose; Stavros J Manousakis; Alexander S Stefanidis; Olga A Papadaki; Helen I Bilianou; Mary C DeVoe; Constantine N Fakiolas; Evangelos G Pissimissis; Christopher D Olympios; Stefanos G Foussas
Journal:  J Am Coll Cardiol       Date:  2002-10-16       Impact factor: 24.094

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  8 in total

1.  Role of pre-procedural C-reactive protein level in the prediction of major adverse cardiac events in patients undergoing percutaneous coronary intervention: a meta-analysisof longitudinal studies.

Authors:  Singh-Baniya Bibek; Yong Xie; Jia-Jia Gao; Zhi Wang; Jing-Feng Wang; Deng-Feng Geng
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 2.  Mechanisms of drug-eluting stent restenosis.

Authors:  Jiro Aoki; Kengo Tanabe
Journal:  Cardiovasc Interv Ther       Date:  2020-11-21

3.  Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis.

Authors:  Raluca-Ileana Mincu; Rolf Alexander Jánosi; Dragos Vinereanu; Tienush Rassaf; Matthias Totzeck
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

Review 4.  Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.

Authors:  Grzegorz K Jakubiak; Natalia Pawlas; Grzegorz Cieślar; Agata Stanek
Journal:  Int J Environ Res Public Health       Date:  2021-11-15       Impact factor: 3.390

5.  Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris.

Authors:  Ayhan Küp; Cüneyt Toprak; Emrah Bayam; Servet İzcı; Abdulkadir Uslu; Mehmet Çelık; İsmail Balaban; Sinan Cerşıt; Süleyman Barutçu; Pınar Demir Gündoğmuş
Journal:  Acta Cardiol Sin       Date:  2020-03       Impact factor: 2.672

6.  Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months after Drug-Eluting Stent Implantation.

Authors:  I-Chang Hsieh; Chun-Chi Chen; Ming-Jer Hsieh; Chia-Hung Yang; Dong-Yi Chen; Shang-Hung Chang; Chao-Yung Wang; Cheng-Hung Lee; Ming-Lung Tsai
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

7.  Predictive value of baseline C-reactive protein for periprocedural myocardial infraction of higher risk stratifications: A retrospective cohort clinical study.

Authors:  Mingyang Yao; Linlin Zhao; Lili Wu; Wenbin Zhang; Yi Luan; Jiale Song; Guosheng Fu; Junhui Zhu
Journal:  Anatol J Cardiol       Date:  2018-09-17       Impact factor: 1.596

8.  Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease.

Authors:  Tomohiro Ohtsuki; Kimio Satoh; Toru Shimizu; Shohei Ikeda; Nobuhiro Kikuchi; Taijyu Satoh; Ryo Kurosawa; Masamichi Nogi; Shinichiro Sunamura; Nobuhiro Yaoita; Junichi Omura; Tatsuo Aoki; Shunsuke Tatebe; Koichiro Sugimura; Jun Takahashi; Satoshi Miyata; Hiroaki Shimokawa
Journal:  J Am Heart Assoc       Date:  2019-11-22       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.